Formulation: A solid
Formal Name: 1,2-benzisoxazole-3-13C-3-methane-13C-sulfonamide-15N
Purity: ≥95%
Formula Markup: C6[13C]2H8N[15N]O3S
Formula Weight: 215,2
Shelf life (days): 1460
CAS Number: 1188265-58-8
Notes: Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide (Item No. 24183) by GC- or LC-MS. Zonisamide is an antiepileptic agent.{41543} It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine (Item No. 21992), but not homovanillic acid (HVA; Item No. 27307) or dihydroxyphenyl acetic acid (DOPAC; Item No. 24912), and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.{45492} Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
English
Deutsch
